Susan Carole Lester, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 63 | 2024 | 21012 | 1.990 |
Why?
|
| Pathology, Surgical | 5 | 2016 | 151 | 1.660 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 15 | 2021 | 926 | 1.570 |
Why?
|
| Nipples | 5 | 2018 | 229 | 1.200 |
Why?
|
| Breast Diseases | 7 | 2024 | 442 | 1.040 |
Why?
|
| Paget's Disease, Mammary | 3 | 2013 | 18 | 0.960 |
Why?
|
| Breast | 14 | 2024 | 1967 | 0.710 |
Why?
|
| Lymph Nodes | 4 | 2022 | 3466 | 0.670 |
Why?
|
| Hyperplasia | 5 | 2021 | 1152 | 0.650 |
Why?
|
| Carcinoma | 3 | 2019 | 2330 | 0.610 |
Why?
|
| Mammography | 22 | 2024 | 2430 | 0.550 |
Why?
|
| Carcinoma, Ductal, Breast | 8 | 2020 | 1085 | 0.540 |
Why?
|
| Ultrasonography, Mammary | 10 | 2023 | 239 | 0.510 |
Why?
|
| Hemangiosarcoma | 1 | 2018 | 215 | 0.510 |
Why?
|
| Dermis | 2 | 2013 | 202 | 0.480 |
Why?
|
| Carcinoma, Lobular | 4 | 2022 | 481 | 0.470 |
Why?
|
| Receptors, Estrogen | 8 | 2023 | 2208 | 0.470 |
Why?
|
| Specimen Handling | 2 | 2009 | 702 | 0.460 |
Why?
|
| Lymphatic Vessels | 1 | 2018 | 358 | 0.450 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 4758 | 0.360 |
Why?
|
| Neoadjuvant Therapy | 3 | 2018 | 2827 | 0.350 |
Why?
|
| Immunohistochemistry | 15 | 2024 | 11076 | 0.330 |
Why?
|
| Medical Errors | 1 | 2016 | 1263 | 0.310 |
Why?
|
| Biopsy | 9 | 2024 | 6766 | 0.290 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 10194 | 0.270 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 2169 | 0.270 |
Why?
|
| Neoplasm Invasiveness | 13 | 2020 | 3595 | 0.270 |
Why?
|
| Fibrocystic Breast Disease | 4 | 2000 | 103 | 0.260 |
Why?
|
| Mastitis | 1 | 2005 | 43 | 0.250 |
Why?
|
| Biopsy, Needle | 9 | 2009 | 1626 | 0.250 |
Why?
|
| Female | 78 | 2024 | 392644 | 0.250 |
Why?
|
| Incidental Findings | 2 | 2006 | 697 | 0.230 |
Why?
|
| Sclerosis | 1 | 2024 | 210 | 0.220 |
Why?
|
| Granuloma | 1 | 2005 | 328 | 0.220 |
Why?
|
| Carney Complex | 1 | 2022 | 15 | 0.210 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2011 | 732 | 0.210 |
Why?
|
| Neoplasm Staging | 11 | 2018 | 11121 | 0.210 |
Why?
|
| Myxoma | 1 | 2022 | 114 | 0.200 |
Why?
|
| Receptors, Progesterone | 3 | 2010 | 1129 | 0.190 |
Why?
|
| Humans | 87 | 2024 | 761504 | 0.190 |
Why?
|
| Neoplasms | 5 | 2023 | 22170 | 0.180 |
Why?
|
| Lymphatic Metastasis | 4 | 2018 | 2915 | 0.180 |
Why?
|
| Axilla | 2 | 2022 | 624 | 0.180 |
Why?
|
| Calcinosis | 5 | 2022 | 1469 | 0.170 |
Why?
|
| World Health Organization | 2 | 2024 | 1322 | 0.170 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2020 | 117 | 0.160 |
Why?
|
| Clinical Protocols | 3 | 2009 | 1440 | 0.160 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 805 | 0.160 |
Why?
|
| Mammaplasty | 2 | 2006 | 1239 | 0.160 |
Why?
|
| Adult | 41 | 2024 | 221177 | 0.150 |
Why?
|
| Middle Aged | 41 | 2024 | 220895 | 0.150 |
Why?
|
| Retrospective Studies | 21 | 2023 | 80636 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2018 | 3514 | 0.140 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 1155 | 0.140 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 287 | 0.140 |
Why?
|
| Cyclins | 2 | 1996 | 594 | 0.130 |
Why?
|
| Fibroma | 1 | 2017 | 190 | 0.130 |
Why?
|
| Pathology, Clinical | 2 | 2018 | 376 | 0.130 |
Why?
|
| Diagnosis, Differential | 9 | 2018 | 12974 | 0.130 |
Why?
|
| Aged | 28 | 2024 | 169289 | 0.120 |
Why?
|
| Phyllodes Tumor | 1 | 2015 | 53 | 0.120 |
Why?
|
| Observer Variation | 5 | 2024 | 2606 | 0.120 |
Why?
|
| Lipoma | 1 | 1996 | 293 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 9177 | 0.110 |
Why?
|
| Papilloma | 1 | 2014 | 140 | 0.110 |
Why?
|
| Giant Cell Arteritis | 1 | 2018 | 306 | 0.110 |
Why?
|
| Mastectomy, Segmental | 2 | 2011 | 955 | 0.110 |
Why?
|
| Aged, 80 and over | 17 | 2019 | 58976 | 0.110 |
Why?
|
| Foreign Bodies | 1 | 1997 | 402 | 0.110 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 1008 | 0.110 |
Why?
|
| Education, Medical, Continuing | 1 | 2018 | 823 | 0.100 |
Why?
|
| Receptor, erbB-2 | 4 | 2024 | 2557 | 0.100 |
Why?
|
| Societies, Medical | 5 | 2013 | 3905 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 2244 | 0.100 |
Why?
|
| Ultrasonography | 6 | 2019 | 5972 | 0.100 |
Why?
|
| Mass Screening | 1 | 2007 | 5428 | 0.100 |
Why?
|
| Cicatrix | 1 | 2017 | 798 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2024 | 15266 | 0.090 |
Why?
|
| Breast Neoplasms, Male | 1 | 2013 | 219 | 0.090 |
Why?
|
| Transformation, Genetic | 2 | 1982 | 192 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 1052 | 0.090 |
Why?
|
| Prognosis | 9 | 2019 | 29625 | 0.090 |
Why?
|
| Dog Diseases | 1 | 2010 | 141 | 0.080 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 151 | 0.080 |
Why?
|
| Papilloma, Intraductal | 1 | 2009 | 21 | 0.080 |
Why?
|
| Mastectomy | 3 | 2013 | 1822 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 36426 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2011 | 2510 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1994 | 1374 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 4174 | 0.060 |
Why?
|
| Stereotaxic Techniques | 3 | 2000 | 555 | 0.060 |
Why?
|
| Probability | 1 | 2010 | 2477 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1999 | 3415 | 0.060 |
Why?
|
| X Chromosome | 2 | 1993 | 816 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 17904 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 7390 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 9420 | 0.060 |
Why?
|
| Cadherins | 2 | 2022 | 903 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 1386 | 0.060 |
Why?
|
| Carcinoma in Situ | 2 | 2000 | 791 | 0.060 |
Why?
|
| Risk Factors | 6 | 2018 | 74206 | 0.050 |
Why?
|
| Mutation | 3 | 2024 | 30052 | 0.050 |
Why?
|
| Medical Records | 1 | 2009 | 1408 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2013 | 2220 | 0.050 |
Why?
|
| Time Factors | 5 | 2018 | 39967 | 0.050 |
Why?
|
| Hybrid Cells | 1 | 1982 | 422 | 0.050 |
Why?
|
| Abscess | 1 | 2005 | 606 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 9280 | 0.050 |
Why?
|
| Neoplasm Proteins | 3 | 2001 | 3617 | 0.050 |
Why?
|
| Lymphoma | 1 | 2010 | 1901 | 0.050 |
Why?
|
| Adenine Phosphoribosyltransferase | 1 | 1980 | 7 | 0.040 |
Why?
|
| United States | 6 | 2013 | 72334 | 0.040 |
Why?
|
| Pentosyltransferases | 1 | 1980 | 62 | 0.040 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 1980 | 69 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2006 | 1271 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 359 | 0.040 |
Why?
|
| False Negative Reactions | 2 | 2011 | 573 | 0.040 |
Why?
|
| Treatment Outcome | 6 | 2018 | 64680 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2023 | 393 | 0.040 |
Why?
|
| Neoplasm Metastasis | 3 | 2024 | 4915 | 0.040 |
Why?
|
| Staining and Labeling | 2 | 2011 | 1085 | 0.040 |
Why?
|
| Skin | 1 | 2013 | 4484 | 0.040 |
Why?
|
| Escherichia coli | 2 | 1991 | 4217 | 0.040 |
Why?
|
| Mucins | 1 | 2022 | 568 | 0.040 |
Why?
|
| Clinical Competence | 2 | 2018 | 4792 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 899 | 0.040 |
Why?
|
| Radiography | 2 | 2007 | 6965 | 0.040 |
Why?
|
| Cell Cycle | 2 | 1996 | 2932 | 0.040 |
Why?
|
| Incidence | 4 | 2014 | 21353 | 0.040 |
Why?
|
| Mitosis | 1 | 2022 | 1187 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1982 | 1171 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2001 | 549 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2001 | 592 | 0.030 |
Why?
|
| Asia | 1 | 2018 | 619 | 0.030 |
Why?
|
| Keratins | 1 | 2017 | 498 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 20570 | 0.030 |
Why?
|
| Pleural Neoplasms | 1 | 2001 | 609 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 1982 | 1756 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2015 | 129 | 0.030 |
Why?
|
| Carbonic Anhydrases | 1 | 1996 | 108 | 0.030 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 39106 | 0.030 |
Why?
|
| Amyloidosis | 2 | 1992 | 817 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2015 | 164 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2018 | 744 | 0.030 |
Why?
|
| Sarcoma | 1 | 2006 | 1801 | 0.030 |
Why?
|
| Mesothelioma | 1 | 2001 | 807 | 0.030 |
Why?
|
| Haplorhini | 1 | 1995 | 525 | 0.030 |
Why?
|
| beta 2-Microglobulin | 2 | 1992 | 329 | 0.030 |
Why?
|
| Australia | 1 | 2018 | 1250 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2024 | 2865 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2017 | 503 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 11742 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2018 | 491 | 0.030 |
Why?
|
| Sex Chromosome Aberrations | 1 | 1993 | 116 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 2020 | 0.030 |
Why?
|
| Metals | 1 | 1997 | 719 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2001 | 1378 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 2396 | 0.030 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 1996 | 384 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1994 | 779 | 0.020 |
Why?
|
| Cysts | 1 | 1997 | 681 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2018 | 1596 | 0.020 |
Why?
|
| Treatment Failure | 2 | 2010 | 2645 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2011 | 1784 | 0.020 |
Why?
|
| Amikacin | 1 | 1991 | 47 | 0.020 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2011 | 62 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 2822 | 0.020 |
Why?
|
| Nuclear Proteins | 2 | 1996 | 5796 | 0.020 |
Why?
|
| Conjugation, Genetic | 1 | 1991 | 116 | 0.020 |
Why?
|
| Antigens, Neoplasm | 2 | 1996 | 1993 | 0.020 |
Why?
|
| Pathology, Veterinary | 1 | 2010 | 3 | 0.020 |
Why?
|
| DNA | 2 | 2022 | 7212 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2023 | 3312 | 0.020 |
Why?
|
| Veterinarians | 1 | 2010 | 13 | 0.020 |
Why?
|
| Venezuela | 1 | 1990 | 73 | 0.020 |
Why?
|
| Phenotype | 2 | 2020 | 16591 | 0.020 |
Why?
|
| Trimethoprim | 1 | 1990 | 78 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 1997 | 1121 | 0.020 |
Why?
|
| Enterobacteriaceae | 1 | 1991 | 161 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2016 | 1742 | 0.020 |
Why?
|
| Cat-Scratch Disease | 1 | 1989 | 23 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 2917 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 1996 | 1119 | 0.020 |
Why?
|
| Boston | 2 | 2014 | 9326 | 0.020 |
Why?
|
| Gentamicins | 1 | 1990 | 243 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 14666 | 0.020 |
Why?
|
| Combined Modality Therapy | 3 | 2007 | 8529 | 0.020 |
Why?
|
| Bone Diseases | 1 | 1992 | 418 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 20098 | 0.020 |
Why?
|
| Sample Size | 1 | 2011 | 841 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2013 | 746 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2010 | 957 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 1992 | 553 | 0.020 |
Why?
|
| Cell Division | 1 | 1995 | 4465 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2001 | 4936 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 1993 | 1393 | 0.020 |
Why?
|
| Cell Line | 3 | 1995 | 15601 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3778 | 0.020 |
Why?
|
| Young Adult | 3 | 2018 | 59243 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 1217 | 0.020 |
Why?
|
| Carrier State | 1 | 1990 | 523 | 0.020 |
Why?
|
| Plasmids | 1 | 1991 | 2269 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 13639 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10090 | 0.020 |
Why?
|
| Algorithms | 3 | 2011 | 14031 | 0.020 |
Why?
|
| Male | 7 | 2022 | 360804 | 0.020 |
Why?
|
| Dogs | 1 | 2010 | 3839 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 5439 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 8547 | 0.020 |
Why?
|
| Prospective Studies | 4 | 2013 | 54425 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2015 | 4003 | 0.020 |
Why?
|
| Rabbits | 1 | 2011 | 4772 | 0.010 |
Why?
|
| China | 1 | 1990 | 2369 | 0.010 |
Why?
|
| Massachusetts | 2 | 2011 | 8830 | 0.010 |
Why?
|
| Ki-67 Antigen | 2 | 1996 | 629 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1990 | 1937 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1989 | 960 | 0.010 |
Why?
|
| Feces | 1 | 1990 | 1497 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1996 | 2020 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2017 | 22176 | 0.010 |
Why?
|
| Adolescent | 4 | 2018 | 88319 | 0.010 |
Why?
|
| Antibodies | 1 | 2011 | 2418 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1993 | 4243 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 1992 | 1797 | 0.010 |
Why?
|
| Phosphoglycerate Kinase | 1 | 1982 | 66 | 0.010 |
Why?
|
| Butyric Acid | 1 | 1982 | 51 | 0.010 |
Why?
|
| Cross Infection | 1 | 1991 | 1422 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 2850 | 0.010 |
Why?
|
| Histamine Antagonists | 1 | 1982 | 92 | 0.010 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 2001 | 23 | 0.010 |
Why?
|
| Disease-Free Survival | 2 | 2003 | 6814 | 0.010 |
Why?
|
| Butyrates | 1 | 1982 | 169 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18395 | 0.010 |
Why?
|
| Disease Progression | 1 | 2018 | 13506 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1982 | 251 | 0.010 |
Why?
|
| Vacuum | 1 | 2000 | 65 | 0.010 |
Why?
|
| Cryoprotective Agents | 1 | 1982 | 128 | 0.010 |
Why?
|
| Genomics | 1 | 2016 | 5821 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1982 | 210 | 0.010 |
Why?
|
| Electrophoresis, Disc | 1 | 1980 | 66 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2008 | 1265 | 0.010 |
Why?
|
| Azacitidine | 1 | 1982 | 336 | 0.010 |
Why?
|
| Animals | 5 | 2011 | 168459 | 0.010 |
Why?
|
| Pleura | 1 | 2001 | 245 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1996 | 6346 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2010 | 2321 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1982 | 646 | 0.010 |
Why?
|
| Automation | 1 | 2000 | 586 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3688 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2003 | 2218 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1980 | 1705 | 0.010 |
Why?
|
| Hematoxylin | 1 | 1996 | 60 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2003 | 2224 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2018 | 41487 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 1996 | 184 | 0.010 |
Why?
|
| Reoperation | 1 | 2006 | 4303 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2003 | 1732 | 0.010 |
Why?
|
| Survival Rate | 2 | 2001 | 12725 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2000 | 3416 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1980 | 3093 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 1996 | 11118 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1996 | 562 | 0.010 |
Why?
|
| Tumor Virus Infections | 1 | 1996 | 438 | 0.010 |
Why?
|
| Cytogenetics | 1 | 1993 | 198 | 0.010 |
Why?
|
| Equipment Design | 1 | 2000 | 3510 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2000 | 1496 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 1900 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1990 | 7407 | 0.010 |
Why?
|
| Premenopause | 1 | 1996 | 1039 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1994 | 17635 | 0.010 |
Why?
|
| Hip | 1 | 1992 | 255 | 0.010 |
Why?
|
| Wrist | 1 | 1992 | 227 | 0.010 |
Why?
|
| Operon | 1 | 1991 | 372 | 0.010 |
Why?
|
| Stromal Cells | 1 | 1996 | 1330 | 0.010 |
Why?
|
| Shoulder | 1 | 1992 | 300 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1980 | 4141 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 8631 | 0.010 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1991 | 188 | 0.010 |
Why?
|
| Klebsiella pneumoniae | 1 | 1991 | 250 | 0.010 |
Why?
|
| DNA Primers | 1 | 1993 | 2819 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1996 | 2202 | 0.000 |
Why?
|
| Drug Resistance, Microbial | 1 | 1991 | 825 | 0.000 |
Why?
|
| Prostatectomy | 1 | 1996 | 1824 | 0.000 |
Why?
|
| Infant | 1 | 1990 | 36192 | 0.000 |
Why?
|
| DNA, Neoplasm | 1 | 1993 | 1745 | 0.000 |
Why?
|
| Child | 2 | 2001 | 80153 | 0.000 |
Why?
|
| DNA Transposable Elements | 1 | 1991 | 755 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1990 | 42230 | 0.000 |
Why?
|
| Receptors, Androgen | 1 | 1993 | 1079 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 6075 | 0.000 |
Why?
|
| Comorbidity | 1 | 2001 | 10508 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 2001 | 12795 | 0.000 |
Why?
|
| Shoulder Joint | 1 | 1992 | 742 | 0.000 |
Why?
|
| Spine | 1 | 1992 | 1118 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1980 | 18965 | 0.000 |
Why?
|
| Papillomavirus Infections | 1 | 1996 | 1613 | 0.000 |
Why?
|
| Recurrence | 1 | 1996 | 8465 | 0.000 |
Why?
|
| Mice | 2 | 1982 | 81525 | 0.000 |
Why?
|
| Base Sequence | 1 | 1993 | 12441 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 13446 | 0.000 |
Why?
|
| Lung | 1 | 2001 | 10000 | 0.000 |
Why?
|
| Alleles | 1 | 1991 | 6863 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2001 | 23995 | 0.000 |
Why?
|
| Pain | 1 | 1992 | 5073 | 0.000 |
Why?
|